{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:08:16Z","timestamp":1785128896292,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.msard.2023.104561","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:33:46Z","timestamp":1676064826000},"page":"104561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1868-3893","authenticated-orcid":false,"given":"Lana Zhovtis","family":"Ryerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Sinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kuhelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Bodhinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Lasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3_suppl","key":"10.1016\/j.msard.2023.104561_bib0001","first-page":"370","article-title":"Exploratory magnetic resonance imaging endpoints from NOVA: a randomized controlled study of the efficacy of 6-week dosing of natalizumab vs continued 4-week treatment for multiple sclerosis","volume":"28","author":"Arnold","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104561_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"2","key":"10.1016\/j.msard.2023.104561_bib0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104561_bib0004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"issue":"20","key":"10.1016\/j.msard.2023.104561_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104561_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116880","article-title":"Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: a prospective 1-year follow-up study","volume":"415","author":"Bringeland","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104561_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117622","article-title":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic","volume":"429","author":"Bringeland","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104561_bib0008","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2023.104561_bib0009","doi-asserted-by":"crossref","first-page":"e53297","DOI":"10.1371\/journal.pone.0053297","article-title":"Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis","volume":"8","author":"Cadavid","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.msard.2023.104561_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/1352458506ms1289oa","article-title":"How to detect cognitive dysfunction at early stages of multiple sclerosis?","volume":"12","author":"Deloire","year":"2006","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2023.104561_bib0011","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104561_bib0013","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/PPA.S134865","article-title":"Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis","volume":"11","author":"Foley","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1016\/j.msard.2023.104561_bib0012","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104561_bib0014","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","article-title":"Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing","volume":"21","author":"Gershon","year":"2012","journal-title":"Qual. Life Res."},{"issue":"10","key":"10.1016\/j.msard.2023.104561_bib0015","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.msard.2023.104561_bib0016","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1212\/CPJ.0000000000000809","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol. Clin. Pract."},{"issue":"2","key":"10.1016\/j.msard.2023.104561_bib0017","article-title":"Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results from MS PATHS","volume":"7","author":"Hersh","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"11","key":"10.1016\/j.msard.2023.104561_bib0018","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104561_bib0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29) a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"16","key":"10.1016\/j.msard.2023.104561_bib0019","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1212\/WNL.0b013e31828cf7f3","article-title":"Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS","volume":"80","author":"Hobart","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104561_bib0021","doi-asserted-by":"crossref","first-page":"e35843","DOI":"10.1371\/journal.pone.0035843","article-title":"Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study","volume":"7","author":"Iaffaldano","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.msard.2023.104561_bib0022","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/13524585211017013","article-title":"The timed 25-foot walk in a large cohort of multiple sclerosis patients","volume":"28","author":"Kalinowski","year":"2022","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104561_bib0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/01312067-200902020-00006","article-title":"Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey","volume":"2","author":"Kamat","year":"2009","journal-title":"Patient"},{"issue":"16","key":"10.1016\/j.msard.2023.104561_bib0024","first-page":"e1560","article-title":"Comparison of the EDSS, timed 25-foot walk, and the 9-hole peg test as clinical trial outcomes in relapsing-remitting multiple sclerosis","volume":"97","author":"Koch","year":"2021","journal-title":"NeurologyNeurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104561_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12955-021-01762-4","article-title":"Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal","volume":"19","author":"Lamu","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"issue":"17","key":"10.1016\/j.msard.2023.104561_bib0026","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"NeurologyNeurology"},{"issue":"5","key":"10.1016\/j.msard.2023.104561_bib0027","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.msard.2023.104561_bib0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC Neurol"},{"issue":"7","key":"10.1016\/j.msard.2023.104561_bib0028","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1007\/s12325-021-01722-w","article-title":"Natalizumab in early relapsing-remitting multiple sclerosis: a 4-year, open-label study","volume":"38","author":"Perumal","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2023.104561_bib0029","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-022-00950-0","article-title":"Improvements in cognitive processing speed, disability, and patient-reported outcomes in patients with early relapsing-remitting multiple sclerosis treated with natalizumab: results of a 4-year, real-world, open-label study","author":"Perumal","year":"2022","journal-title":"CNS Drugs"},{"issue":"13","key":"10.1016\/j.msard.2023.104561_bib0031","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458514530489","article-title":"Responder definition of the multiple sclerosis impact scale physical impact subscale for patients with physical worsening","volume":"20","author":"Phillips","year":"2014","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2023.104561_bib0032","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.104561_bib0033","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7224\/1537-2073.2013-017","article-title":"Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle","volume":"16","author":"Ratchford","year":"2014","journal-title":"Int J MS Care"},{"key":"10.1016\/j.msard.2023.104561_bib0034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1477-7525-10-155","article-title":"Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study","volume":"10","author":"Stephenson","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"issue":"5","key":"10.1016\/j.msard.2023.104561_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1352458511426735","article-title":"Unemployment in multiple sclerosis: the contribution of personality and disease","volume":"18","author":"Strober","year":"2012","journal-title":"Mult. Scler."},{"issue":"17","key":"10.1016\/j.msard.2023.104561_bib0036","first-page":"e1579","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"NeurologyNeurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104561_bib0037","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ene.12618","article-title":"Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM","volume":"22","author":"Voloshyna","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2023.104561_bib0038","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson","year":"2019","journal-title":"NeurologyNeurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:38Z","timestamp":1761901538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"alternative-id":["S2211034823000652"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104561","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104561"}}